Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia).
- Conditions
- HIV and hyperlipidemia or mixed dyslipidemia.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 23.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- EUCTR2015-004735-12-PT
- Lead Sponsor
- Amgen Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 467
* Subject has provided written informed consent
* Male or female = 18 years of age at signing of informed consent
* Known HIV infection with stable HIV therapy for = 6 months prior to
randomization and not expected to change during the duration of study participation. Stable HIV therapy is defined as no new agents added and no dose change of any HIV drug within 6 months prior to randomization
* Cluster of differentiation 4 (CD4) = 250 cells/mm3 for = 6 months prior to randomization
* HIV viral load = 50 copies/mL at screening and = 200 copies/mL for = 6 months prior to randomization
* Subject on stable lipid-lowering therapy for = 4 weeks prior to randomization
and not expected to change during the duration of study participation. Subjects should be on maximally tolerated dose of statins.
* Subject without known clinical atherosclerotic CVD (ASCVD): fasting LDL-C of = 100 mg/dL (2.6 mmol/L) or non-HDL-C of = 130 mg/dL (3.4 mmol/L) as determined by the central laboratory at screening. Subject with known clinical ASCVD: fasting LDL-C of = 70 mg/dL (1.8 mmol/L) or non-HDL-C of = 100mg/dL (2.6 mmol/L) as determined by the central aboratory.
* Fasting triglycerides = 600 mg/dL (6.8 mmol/L) as determined by central laboratory during screening
* Subject tolerates screening placebo injection
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 420
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
* Subject taking a combination of background lipid-lowering therapy and HIV therapy known to have significant drug-drug interaction
* New York Heart Association III or IV heart failure, or last known left ventricular ejection fraction < 30%
* Known opportunistic infection/AIDS defining illness (including but not limited to candidiasis of bronchi, trachea, esophagus, or lungs, invasive cervical cancer, coccidioidomycosis, cryptococcosis, chronic intestinal (> 1-month duration) cryptosporidiosis, cytomegalovirus disease (particularly cytomegalovirus [CMV] retinitis), HIV-related encephalopathy, herpes simplex: chronic ulcer(s) (> 28 days duration); or bronchitis, pneumonitis, or esophagitis, histoplasmosis,
chronic intestinal (> 28 days duration) isosporiasis, Kaposi's sarcoma,
lymphoma, mycobacterium avium complex, tuberculosis, pneumocystis carinii pneumonia, recurrent pneumonia, progressive multifocal leukoencephalopathy, salmonella septicemia, toxoplasmosis of brain, or wasting syndrome due to HIV within 1 year prior to randomization
* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization
* Type 1 diabetes, new-onset (hemoglobin A1c [HbA1c] = 6.5% or fasting plasma glucose = 126 mg/dL at screening without known diagnosis) or poorly controlled (HbA1c = 10%) type 2 diabetes by central laboratory during screening
* Uncontrolled hypertension defined as sitting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg during screening
* Subject has taken a cholesterylester transfer protein inhibitor in the last 12 months prior to randomization
* Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate < 30 mL/min/1.73 m2 during screening
* Persistent active liver disease or hepatic dysfunction defined as Child-Pugh score of C. Stable (in the opinion of the primary investigator and with aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 5 times upper limit of normal [ULN] and not expected to require new treatment[s] during study) chronic hepatitis C of at least 1 year duration prior to randomization is allowed
* Female subject of childbearing potential not willing to use acceptable method(s) of effective birth control during treatment with IP and for an additional 15 weeks after the end of treatment with IP. Female subjects of non-childbearing potential are not required to use contraception during the study and include those who have had a hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or who are postmenopausal.
* Female subject is pregnant or breast feeding, planning to become pregnant or planning to breastfeed during treatment with IP and/or within 15 weeks after the end of treatment with IP
* Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years prior to randomization
* Subject has previously received evolocumab or any other therapy to inhibit PCSK9
* Currently receiving treatment in another investigational device or drug study, or < 30 days before randomization since ending treatment on another investigational device or drug study(s) or planning to receive other investigational procedures while participating in this study
* Subject has known sensitivity to any of the active substances or their excipients to be administered during dosing, eg, carboxy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method